TY - JOUR
T1 - Constitutive androstane receptor regulates the intestinal mucosal response to injury
AU - Hudson, Grace M.
AU - Flannigan, Kyle L.
AU - Erickson, Sarah L.
AU - Vicentini, Fernando A.
AU - Zamponi, Alexandra
AU - Hirota, Christina L.
AU - Alston, Laurie
AU - Altier, Christophe
AU - Ghosh, Subrata
AU - Rioux, Kevin P.
AU - Mani, Sridhar
AU - Chang, Thomas K.
AU - Hirota, Simon A.
N1 - Funding Information:
This work was supported by the Live Cell Imaging Facility (funded by the Snyder Institute at the University of Calgary), as well as the Intestinal Inflammation Tissue Bank at the University of Calgary. SAH's salary is supported by the Canadian Institutes for Health Research's Canada Research Chair program (Tier II CRC in Host–Microbe Interactions and Chronic Disease) and SAH's lab is supported by an infrastructure grant provided by the Canadian Foundation for Innovation John R. Evans Leaders Fund. The studies reported were supported by operating funds from Crohn's & Colitis Canada (SAH and TKHC co-investigators); NSERC (#RGPIN-2016-03842, SAH) and the Dr. Lloyd Sutherland Investigatorship in IBD/GI Research (SAH). KLF is supported by the Beverly Philips postdoctoral fellowship through the Snyder Institute for Chronic Diseases at the University of Calgary. SM's lab is supported by NIH grants (CA127231, CA161879); Broad Medical Research Program - Crohn's & Colitis Foundation (CCFA) Investigator Award (Proposal No. 262520; Grant# 362520). The authors would also like to acknowledge Dr. Keith Sharkey's co-supervision of FAV throughout the course of his graduate training.
Publisher Copyright:
© 2017 The British Pharmacological Society
PY - 2017
Y1 - 2017
N2 - Background and Purpose: The pathogenesis of the inflammatory bowel diseases (IBD), comprising Crohn's disease (CD) and ulcerative colitis (UC), involves aberrant interactions between a genetically susceptible individual, their microbiota and environmental factors. Alterations in xenobiotic receptor expression and function are associated with increased risk for IBD. Here, we have assessed the role of the constitutive androstane receptor (CAR), a xenobiotic receptor closely related to the pregnane X receptor, in the regulation of intestinal mucosal homeostasis. Experimental Approach: CAR expression was assessed in intestinal mucosal biopsies obtained from CD and UC patients, and in C57/Bl6 mice exposed to dextran sulphate sodium (DSS; 3.5% w/v in drinking water) to evoke intestinal inflammation and tissue damage. CAR-deficient mice were exposed to DSS and mucosal healing assessed. Modulation of wound healing by CAR was assessed in vitro. The therapeutic potential of CAR activation was evaluated, using 3,3′,5,5′-tetrachloro-1,4-bis(pyridyloxy)benzene (TCPOBOP), a selective rodent CAR agonist. Key Results: CAR expression was reduced in CD and UC samples, compared with expression in healthy controls. This was reproduced in our DSS studies, where CAR expression was reduced in colitic mice. CAR-deficient mice exhibited reduced healing following DSS exposure. In vitro, CAR activation accelerated intestinal epithelial wound healing by enhancing cell migration. Lastly, treating mice with TCPOBOP, following induction of colitis, enhanced mucosal healing. Conclusion and Implications: Our results support the notion that xenobiotic sensing is altered during intestinal inflammation, and suggest that CAR activation may prove effective in enhancing mucosal healing in patients with IBD.
AB - Background and Purpose: The pathogenesis of the inflammatory bowel diseases (IBD), comprising Crohn's disease (CD) and ulcerative colitis (UC), involves aberrant interactions between a genetically susceptible individual, their microbiota and environmental factors. Alterations in xenobiotic receptor expression and function are associated with increased risk for IBD. Here, we have assessed the role of the constitutive androstane receptor (CAR), a xenobiotic receptor closely related to the pregnane X receptor, in the regulation of intestinal mucosal homeostasis. Experimental Approach: CAR expression was assessed in intestinal mucosal biopsies obtained from CD and UC patients, and in C57/Bl6 mice exposed to dextran sulphate sodium (DSS; 3.5% w/v in drinking water) to evoke intestinal inflammation and tissue damage. CAR-deficient mice were exposed to DSS and mucosal healing assessed. Modulation of wound healing by CAR was assessed in vitro. The therapeutic potential of CAR activation was evaluated, using 3,3′,5,5′-tetrachloro-1,4-bis(pyridyloxy)benzene (TCPOBOP), a selective rodent CAR agonist. Key Results: CAR expression was reduced in CD and UC samples, compared with expression in healthy controls. This was reproduced in our DSS studies, where CAR expression was reduced in colitic mice. CAR-deficient mice exhibited reduced healing following DSS exposure. In vitro, CAR activation accelerated intestinal epithelial wound healing by enhancing cell migration. Lastly, treating mice with TCPOBOP, following induction of colitis, enhanced mucosal healing. Conclusion and Implications: Our results support the notion that xenobiotic sensing is altered during intestinal inflammation, and suggest that CAR activation may prove effective in enhancing mucosal healing in patients with IBD.
UR - http://www.scopus.com/inward/record.url?scp=85018553740&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85018553740&partnerID=8YFLogxK
U2 - 10.1111/bph.13787
DO - 10.1111/bph.13787
M3 - Article
C2 - 28320072
AN - SCOPUS:85018553740
SN - 0007-1188
VL - 174
SP - 1857
EP - 1871
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
IS - 12
ER -